Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

UK

Bristol Myers Squibb logo

Opdivo boosts survival in head and neck cancer by 30%

Pivotal trial of BMS’ PD-1 inhibitor shows "significant benefit" in overall survival

- PMLiVE

New biosimilars group will tackle slow uptake in UK

Has pledged to increase access to lower-priced versions of biologic drugs

- PMLiVE

AbbVie hepatitis C combo shows high cure rates

Presents promising new phase II data across all six major HCV genotypes

- PMLiVE

FDA panel says no to quick approval of Clovis’ rociletinib

Recommends waiting for phase III trial results after "serious" safety concerns

Nestlé begins mHealth trial

Launches trials in healthly ageing research programme

AstraZeneca AZ

AZ gets $100m from Lilly as Alzheimer’s drug progresses

BACE inhibitor candidate displays ‘encouraging’ positive safety data

- PMLiVE

Pfizer’s PCSK9 inhibitor clears another phase III trial

Bococizumab will compete with Praluent and Repatha if it reaches the market

- PMLiVE

J&J drops NGF blocker fulranumab

Says decision to return rights to Amgen based on “strategic portfolio prioritisation”

- PMLiVE

Norman Lamb: Health savings ‘unachievable’ under current approach

Former minister says health system's ‘existential challenge’ needs new thinking

AstraZeneca AZ

AZ’s Brilinta disappoints in stroke trial

Antiplatelet drug fails to demonstrate significant benefit in ischaemic stroke

- PMLiVE

Applying real-world evidence to orphan drugs

How to prove pharma’s innovative treatments really can bring about positive outcomes

- PMLiVE

Amgen and UCB’s romosozumab hits goals in male osteoporosis

Firms will discuss data with regulators before planning a new male licence application

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links